Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Valérie Lagarde"'
Autor:
Aurélie Bedel, Jean-Max Pasquet, Eric Lippert, Miguel Taillepierre, Valérie Lagarde, Sandrine Dabernat, Pierre Dubus, Lucie Charaf, François Beliveau, Hubert de Verneuil, Emmanuel Richard, François-Xavier Mahon, François Moreau-Gaudry
Publikováno v:
PLoS ONE, Vol 8, Iss 8, p e71596 (2013)
Chronic myeloid leukemia disease (CML) found effective therapy by treating patients with tyrosine kinase inhibitors (TKI), which suppress the BCR-ABL1 oncogene activity. However, the majority of patients achieving remission with TKI still have molecu
Externí odkaz:
https://doaj.org/article/20baab42acec45e29178f6ba8784b5bb
Autor:
Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon
Supplementary Table 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a07f07a2ee0e83f0923d451598bac1e
https://doi.org/10.1158/0008-5472.22375482
https://doi.org/10.1158/0008-5472.22375482
Autor:
Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon
Supplementary Figure 1 from Evidence that Resistance to Nilotinib May Be Due to BCR-ABL, Pgp, or Src Kinase Overexpression
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::15ab1f3bff6bbe20196d7882c1f25cc6
https://doi.org/10.1158/0008-5472.22375485.v1
https://doi.org/10.1158/0008-5472.22375485.v1
Autor:
Jean-Max Pasquet, Serge Roche, Gabriel Etienne, Cédric Leroy, Paul W. Manley, Coralie Belanger, Franck Nicolini, Béatrice Turcq, Francis Belloc, Valérie Lagarde, Sandrine Hayette, François-Xavier Mahon
Targeting the tyrosine kinase activity of Bcr-Abl is an attractive therapeutic strategy in chronic myeloid leukemia (CML) and in Bcr-Abl–positive acute lymphoblastic leukemia. Whereas imatinib, a selective inhibitor of Bcr-Abl tyrosine kinase, is n
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d45ccba8171317d1789fbeada0384d9a
https://doi.org/10.1158/0008-5472.c.6497844
https://doi.org/10.1158/0008-5472.c.6497844
Autor:
Gwénaële Jégou, Eric Lippert, Francois-Xavier Mahon, Béatrice Turcq, Olivier Mansier, Eric Chevet, Konstantinos Voutetakis, Diana Pelizzari Raymundo, Pierre-Yves Dumas, Kim Barroso, Chloé James, Vincent Praloran, Valérie Lagarde, Valérie Prouzet-Mauléon, Aristotelis Chatziioannou, Jean-François Viallard, Jean-Max Pasquet, Aurélie Chauveau
Publikováno v:
Cancers
Cancers, MDPI, 2019, 11 (12), pp.1921. ⟨10.3390/cancers11121921⟩
Volume 11
Issue 12
Cancers, 2019, 11 (12), pp.1921. ⟨10.3390/cancers11121921⟩
Cancers, MDPI, 2019, 11 (12), pp.1921. ⟨10.3390/cancers11121921⟩
Volume 11
Issue 12
Cancers, 2019, 11 (12), pp.1921. ⟨10.3390/cancers11121921⟩
Background: Mutations in CALR observed in myeloproliferative neoplasms (MPN) were recently shown to be pathogenic via their interaction with MPL and the subsequent activation of the Janus Kinase &ndash
Signal Transducer and Activator of Transcri
Signal Transducer and Activator of Transcri
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f8debe6910315ff63ded02dc065b3197
http://hdl.handle.net/20.500.12278/12191
http://hdl.handle.net/20.500.12278/12191
Publikováno v:
Journal of Translational Proteomics Research. 2:15-19
Autor:
Bruno Robert, Isabelle Vigon, Pierre-Yves Dumas, Vanessa Desplat, Serge Roche, Francois-Xavier Mahon, Valérie Prouzet-Mauléon, Wilhem Leconet, Romain Gioia, Claire Trégoat, Jean-Max Pasquet, Audrey Sirvent, Vincent Praloran, Arnaud Villacreces, Valérie Lagarde, Eric Lippert
Publikováno v:
Journal of Pathology
Journal of Pathology, Wiley, 2015, 237 (1), pp.14--24. ⟨10.1002/path.4561⟩
Journal of Pathology, Wiley, 2015, 237 (1), pp.14--24. ⟨10.1002/path.4561⟩
A tyrosine kinase network composed of the TAM receptor AXL and the cytoplasmic kinases LYN and SYK is involved in nilotinib-resistance of chronic myeloid leukaemia (CML) cells. Here, we show that the E3-ubiquitin ligase CBL down-regulation occurring
Autor:
Marc Bonneu, Valérie Prouzet-Mauléon, Francois-Xavier Mahon, Stéphane Claverol, Bruno Cardinaud, Valérie Lagarde, Anne-Sophie Espadinha
Publikováno v:
Oncotarget
// Anne-Sophie Espadinha 1, 2 , Valerie Prouzet-Mauleon 1, 2 , Stephane Claverol 3 , Valerie Lagarde 1, 2 , Marc Bonneu 3, 4 , Francois-Xavier Mahon 1, 2 and Bruno Cardinaud 1, 2, 4 1 University of Bordeaux, INSERM U1035, Bordeaux, France 2 Universit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0a9180c68bef64c4ce8c45646e093176
http://hdl.handle.net/20.500.12278/10328
http://hdl.handle.net/20.500.12278/10328
Autor:
Bruno Cardinaud, Patrick Legembre, Valérie Lagarde, Muriel Priault, Claire Drullion, Eric Lippert, Francois-Xavier Mahon, Romain Gioia, Jean-Max Pasquet
Publikováno v:
Leukemia Research and Treatment
Leukemia Research and Treatment, 2012, 2012, pp.861301. ⟨10.1155/2012/861301⟩
Leukemia Research and Treatment, 2012, 2012, pp.861301. ⟨10.1155/2012/861301⟩
We used K562 cells sensitive or generated resistant to imatinib or nilotinib to investigate their response to mycophenolic acid (MPA). MPA induced DNA damage leading to cell death with a minor contribution of apoptosis, as revealed by annexin V label
Autor:
Gabriel Etienne, Maryse Dupouy, Patricia Costaglioli, Claudine Chollet, Valérie Lagarde, Jean-Max Pasquet, Josy Reiffers, Bertrand Garbay, François-Xavier Mahon, Béatrice Turcq
Publikováno v:
Disease Markers, Vol 30, Iss 5, Pp 221-227 (2011)
Disease markers
Disease Markers
Disease Markers, Hindawi, 2021, 30 (5), pp.221-7. ⟨10.3233/DMA-2011-0777⟩
Disease markers
Disease Markers
Disease Markers, Hindawi, 2021, 30 (5), pp.221-7. ⟨10.3233/DMA-2011-0777⟩
Objective: Imatinib mesylate is a tyrosine kinase inhibitor used as first line treatment in chronic myeloid leukaemia. Despite a remarkable effectiveness, treatment failure cases have been reported in 20 percent of CML patients. The identification of